Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T39078 | ||||
Target Name | Calcium-activated potassium channel (KCN) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Charybdotoxin | Drug Info | IC50 = 30 nM | [7] | |
Chlorzoxazone | Drug Info | EC50 = 30000 nM | [3] | ||
Halofantrine | Drug Info | IC50 = 2.98 nM | [4] | ||
Quinine | Drug Info | IC50 = 100000 nM | [7] | ||
AVE0118 | Drug Info | IC50 = 1100 nM | [6] | ||
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide | Drug Info | IC50 = 9 nM | [1] | ||
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole | Drug Info | IC50 = 20 nM | [2] | ||
2,2,2-tris-(3-fluorophenyl)-acetamide | Drug Info | IC50 = 13 nM | [1] | ||
2,2,2-tris-(4-fluorophenyl)-acetamide | Drug Info | IC50 = 14 nM | [1] | ||
2,2-bis-(2-fluorophenyl)-2-phenylacetamide | Drug Info | IC50 = 30 nM | [1] | ||
2,2-bis-(3-fluorophenyl)-2-phenylacetamide | Drug Info | IC50 = 30 nM | [1] | ||
2-(2,4-difluorophenyl)-2,2-diphenylacetamide | Drug Info | IC50 = 34 nM | [1] | ||
2-(2-chlorophenyl)-2,2-diphenylethanamide | Drug Info | IC50 = 20 nM | [1] | ||
2-(3,4-Difluorophenyl)-2,2-diphenylacetamide | Drug Info | IC50 = 14 nM | [1] | ||
2-fluorophenyl-2,2-diphenylacetamide | Drug Info | IC50 = 15 nM | [1] | ||
2-trityl-4,5-dihydrooxazole | Drug Info | IC50 = 4300 nM | [1] | ||
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one | Drug Info | IC50 = 10000 nM | [2] | ||
4-fluorophenyl-2,2-diphenylacetamide | Drug Info | IC50 = 40 nM | [1] | ||
5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one | Drug Info | IC50 = 2100 nM | [2] | ||
Bis(4-fluorophenyl)-2-fluorophenylacetamide | Drug Info | IC50 = 10 nM | [1] | ||
ICA-17043 | Drug Info | IC50 = 12 nM | [1] | ||
N,N-dimethyl-2,2,2-triphenylacetamide | Drug Info | IC50 = 3150 nM | [1] | ||
N-ethyl-2,2,2-triphenylacetamide | Drug Info | IC50 = 1750 nM | [1] | ||
N-methyl-2,2,2-triphenylacetamide | Drug Info | IC50 = 550 nM | [1] | ||
Triphenylacetic acid methyl ester | Drug Info | IC50 = 330 nM | [1] | ||
TRIPHENYLMETHANAMINE | Drug Info | IC50 = 70 nM | [1] | ||
Action against Disease Model | Halofantrine | Drug Info | The drug resistance profiles of Plasmodi uM falcipar uM isolated from four regions in Kenya were analyzed for drug resistance profiles. We observed variability in resistance to a broad range of antimalarial drugs across Kenya as determined from in vitro drug susceptibility screening and genotyping analysis.IC50 for Plasmodi uM falcipar uM isolates from Kericho, Kenya: 0.2 ng/mL | [5] | |
References | |||||
REF 1 | Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. | ||||
REF 2 | Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. | ||||
REF 3 | Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. Brain Res. 2003 Jan 3;959(1):86-97. | ||||
REF 4 | In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg. 1992 Oct;47(4):521-7. | ||||
REF 5 | Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. Antimicrob Agents Chemother. 2004 Sep;48(9):3598-601. | ||||
REF 6 | Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology. Curr Top Med Chem. 2009;9(5):436-51. | ||||
REF 7 | A charybdotoxin-sensitive, Ca(2+)-activated K+ channel with inward rectifying properties in brain microvascular endothelial cells: properties and activation by endothelins. J Neurochem. 1995 Sep;65(3):1274-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.